Everything below concerns LC-MS. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-27. Numbers and descriptions here follow the published literature rather than marketing material.
NMN is generally handled as a hygroscopic and light-sensitive solid in laboratory settings. Recommended storage is typically at -20°C or below, often under desiccation and protected from light. Aqueous solutions are less stable than the solid and may degrade through hydrolysis or other pathways, so fresh preparation is common for analytical work. Repeated freeze-thaw cycles can reduce sample integrity. Stability depends on pH, temperature, buffer composition, and the presence of metal ions, so specific shelf-life values should be determined experimentally rather than assumed.
Quality control for NMN samples often includes purity determination by HPLC, identity confirmation by mass spectrometry or NMR, and water content measurement by Karl Fischer titration. Certificates of analysis may report residual solvents, heavy metals, and microbial limits depending on the intended use. Purity values are method-dependent, so a stated percentage should be interpreted alongside the analytical procedure and detection wavelength. Reference standards help ensure that retention times and spectral data are comparable across laboratories. Researchers increasingly request independent verification because supply chains for specialty chemicals can vary in documentation.
Common laboratory methods for NMN include high-performance liquid chromatography with ultraviolet detection, liquid chromatography coupled to mass spectrometry, and nuclear magnetic resonance spectroscopy. Because the nicotinamide ring absorbs ultraviolet light, HPLC-UV at wavelengths near 260 nm can be used for purity assessment. LC-MS and LC-MS/MS provide greater sensitivity and are often applied to biological samples. Identification typically relies on matching retention time, mass-to-charge ratio, and fragmentation pattern to a reference standard.
Nicotinamide mononucleotide, usually shortened to NMN, is a naturally occurring nucleotide. Its structure consists of a nicotinamide base linked to a ribose sugar that carries a phosphate group. In cells, NMN serves as an intermediate in the salvage pathway that produces nicotinamide adenine dinucleotide, or NAD+. Because NAD+ participates in many oxidation-reduction reactions, NMN sits near central metabolic processes. The compound is not a drug in most jurisdictions and is discussed mainly in biochemistry and nutrition research.
The term NMN commonly refers to the beta isomer, in which the nicotinamide group is attached to the ribose through a beta-glycosidic bond. Commercial material may be supplied as the free acid or as a salt, such as a sodium salt, which affects molecular weight and water solubility. Related compounds include nicotinamide riboside and NAD+ itself, but these are distinct molecules with different formulas and cellular handling. Laboratory research often uses the beta form because it matches the naturally occurring configuration found in biological systems.
| Property | Value | Notes |
|---|---|---|
| Solubility | Water-soluble | Polar nucleotide |
| Typical storage | -20°C or below | Desiccated, protected from light |
| Common analytical method | HPLC-UV | Detection near 260 nm |
| Identity confirmation | LC-MS or NMR | Compared with reference standard |
| Purity assessment | HPLC peak area | Method-dependent |
Identity and purity are usually assessed with complementary methods. Nuclear magnetic resonance spectroscopy can confirm the molecular structure and distinguish anomeric forms. High-performance liquid chromatography with ultraviolet detection or mass spectrometry is common for assay and related-substance testing. Mass spectrometry also supports trace quantification in biological samples, often with isotope-labeled internal standards. Because NMN lacks a strong chromophore, some ultraviolet methods require careful wavelength selection or derivatization, and laboratories may validate each approach for its intended matrix.
Commercial NMN is produced through enzymatic or chemical routes, and the resulting material can vary in purity, counterion, and residual solvent content. Buyers typically rely on certificates of analysis, but independent verification through third-party laboratories provides stronger assurance. Regulatory treatment differs by country; in the United States, NMN has been subject to shifting guidance about its status as a dietary supplement, while other markets permit sales under local rules. No universal pharmacopeial monograph exists for NMN, so specifications often come from suppliers, research protocols, or regional requirements.
Solid NMN is generally handled as a moisture-sensitive compound. Dry material stored desiccated at low temperature, protected from light, tends to remain stable for extended periods. Aqueous solutions are less stable and can undergo hydrolysis, especially at elevated temperature or alkaline pH. The anomeric form also matters: beta-NMN is the naturally occurring form, while alpha-NMN can appear as a synthetic impurity. Purity and storage conditions therefore influence both analytical results and experimental reproducibility.
NMN occurs in many living systems, including bacteria, yeast, plants, and mammals. Dietary sources are present in foods such as edamame, avocado, broccoli, and various meats, but amounts vary widely and are generally lower than those used in research settings. Laboratory production often relies on enzymatic synthesis or chemical phosphorylation of nicotinamide riboside, and commercial material is typically supplied as a white to off-white powder. Because NMN is hygroscopic and sensitive to heat, moisture, and pH extremes, its handling requires care to preserve identity and purity. Aqueous preparation should be done with attention to pH and temperature to limit hydrolysis.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in cells. Its structure consists of a nicotinamide ring linked to ribose phosphate, and the compound serves as an intermediate in the salvage pathway for nicotinamide adenine dinucleotide, or NAD+. In this pathway, nicotinamide phosphoribosyltransferase converts nicotinamide and phosphoribosyl pyrophosphate into NMN, after which NMN adenylyltransferase attaches an adenylate group to produce NAD+. Because NAD+ participates in redox reactions and signaling, NMN occupies a central position in cellular metabolism. The molecule is distinct from nicotinamide riboside, though the two are related in NAD+ precursor research.
Beyond its intracellular synthesis, NMN can be taken up from the extracellular environment, although the routes are still debated. Some evidence points to direct transport into cells through specific transporters, while other work suggests dephosphorylation to nicotinamide riboside followed by cellular uptake. Once inside, NMN can be converted to NAD+ by NMN adenylyltransferases; the relative contribution of these routes may differ by tissue, species, and experimental conditions. Researchers continue to investigate which mechanisms dominate in intact organisms and how they affect measured NAD+ levels. Direct measurement in tissues remains technically challenging because NMN can be rapidly metabolized during sample collection.
Quality control for NMN typically checks identity, assay purity, residual solvents, heavy metals, and microbial limits, depending on the intended use and market. A certificate of analysis may report appearance, solubility, water content, and storage recommendations. Independent verification can compare chromatographic retention time and mass spectrum against a certified reference standard. Regulatory expectations differ between research chemicals, dietary ingredients, and pharmaceutical products. Impurity profiles and stability data are often requested for product approval, and open questions remain about how best to standardize NMN measurements across laboratories.
NMN is a polar, water-soluble nucleotide. In solid form it is usually a white to off-white powder. The compound is sensitive to heat, light, moisture, and extremes of pH, and aqueous solutions tend to degrade faster than dry material. Recommended storage for research samples is typically -20 °C or below in a sealed, desiccated container protected from light. Repeated freeze-thaw cycles should be avoided, and these handling practices help maintain identity and purity during laboratory use.
Dietary sources of NMN include small amounts in certain vegetables, fruits, and other foods, although exact values vary by sample and method. Endogenous NMN concentrations are tightly regulated and often low, making measurement in blood or tissues technically demanding. After oral intake, NMN is thought to be rapidly metabolized in the intestine and liver, and intact NMN may not reach all tissues at high levels. Some rodent studies report increases in tissue NAD+ after oral NMN, while human data remain limited and sometimes rely on blood NAD+ metabolites rather than direct tissue measures.
Research on NMN has focused on aging, metabolic regulation, exercise capacity, and insulin sensitivity, but findings are preliminary. Many human trials are small, short in duration, and use different endpoints, which complicates comparison across studies. No national regulator has approved NMN as a therapeutic drug for any indication. In some countries it is sold as a supplement or research chemical, while other jurisdictions have questioned its status under food or supplement laws. Claims about extending human lifespan or reversing aging are not supported by established clinical evidence.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms, including bacteria, plants, and mammals. Its structure consists of a nicotinamide ring attached to a ribose-phosphate group. NMN functions as an intermediate in the NAD+ salvage pathway, a recycling route that regenerates nicotinamide adenine dinucleotide. The enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+.
The foundations for Jung's typology of psychological types were in his early research at the Burghölzli Hospital. Through the Word Association Experiment, Jung provided the first empirical evidence of "complexes", observing that individuals showed distinct patterns in how they responded to emotional disturbances: some subjects were consistently oriented toward the objective meaning of the stimulus (extraverted tendency), while others were derailed by internal, subjective associations (introverted tendency). Jung interpreted what he saw as a fundamental divergence in how psychic energy (libido) moved in psychiatric patients. He noted that in hysteria, energy flowed outward toward the object, whereas in dementia praecox (schizophrenia), energy withdrew into a subjective inner world. By 1913, Jung concluded that these were not merely symptoms of illness but exaggerated manifestations of normal psychological orientations. The further differentiation of the four psychological functions (thinking, feeling, sensation, and intuition) emerged from Jung's period of intense self-experimentation between 1913 and 1917. Documented in The Red Book (Liber Novus), Jung utilised the method of active imagination to observe his own mental processes. This introspection allowed him to map how certain functions dominate consciousness while their opposites remain "inferior" and unconscious. By comparing these personal findings with the case histories of his patients, Jung moved from a simple two-fold model (extraversion/introversion) to the complex eight-fold functional system published in 1921.
=== Effectiveness evaluation === A 2013 article published in The Lancet reported that the MenAfriVac vaccination campaign in Chad reduced meningitis incidence by 94%. In three regions of Chad, approximately 1.8 million people from 1 to 29 years old received a single dose of the vaccine in December 2011. Vaccinating 70% of the population in that age group is enough to create "herd immunity". During the 2012 meningitis season no cases of the meningococcus sub-type serogroup A caused disease in places where mass vaccination took place. Carriers of serogroup A were found to decrease by more than 97% post-vaccination. Surveillance is needed to continue for several more years to establish the length of effective period of the vaccine and whether other meningococci serogroups may surge to replace serogroup A. In November 2015, a special collection of 29 articles was published in the journal Clinical Infectious Diseases—with guest editors from Public Health England and the former Meningitis Vaccine Project about the steps taken for the development, introduction, and evaluation of MenAfriVac. Immunization with MenAfriVac has led to the control and near elimination of deadly meningitis A disease in the African "meningitis belt". In 2013, only four laboratory-confirmed cases of meningitis A were reported by the 26 countries in the meningitis belt. But scientists warned that unless countries within the belt incorporate the meningitis A vaccine in routine immunization schedules for infants, there is a risk that the disease could rebound in 15 years' time.
== Use and effects == According to Alexander Shulgin in his book TiHKAL (Tryptamines I Have Known and Loved), DET's dose range is 50 to 100 mg orally and its duration is 2 to 4 hours. It was also assessed at oral doses of 44 to 400 mg, though 150 mg was described as "a little too much" and the 400 mg dose was simply described as "too high". Its onset is 40 minutes to more than 1 hour and peak effects occurred at just over 1 hour. In addition to oral administration, DET was assessed by smoking at doses of 40 to 90 mg, by subcutaneous injection at a dose of 40 mg, by intramuscular injection at a dose of 60 mg, and by intravenous injection at a dose of 60 mg. By these routes, it has a faster onset than when taken orally. The drug is said to taste terrible when smoked, like "burning plastic". DET was initially assumed to be inactive orally similarly to dimethyltryptamine (DMT), but this proved to be incorrect. The effects of DET have been reported to include similar "illusions" and hallucinations" as DMT, a wave-like time course of effects, closed-eye visuals, open-eye visuals, auditory and olfactory hallucinations, synesthesia, feeling like in another world, cosmic thinking, mystical and philosophical feelings, dream-like mysteriousness of objects, greater emotional significance of objects, peoples' faces seeming "mask-like", enhanced appreciation of art, architecture, and music, feeling like a small child perceiving the world and discovering it anew, time dilation, enjoyment and euphoria, increased empathy, and emotional insights.
Sources: en.wikipedia.org
At the end of the electrophoretic separation, all proteins are sorted by size and can then be analyzed by other methods, e. g. protein staining such as Coomassie staining (most common and easy to use), silver staining (highest sensitivity), stains all staining, Amido black 10B staining, Fast green FCF staining, fluorescent stains such as epicocconone stain and SYPRO orange stain, and immunological detection such as the Western Blot. The fluorescent dyes have a comparatively higher linearity between protein quantity and color intensity of about three orders of magnitude above the detection limit (the quantity of protein that can be estimated by color intensity). When using the fluorescent protein dye trichloroethanol, a subsequent protein staining is omitted if it was added to the gel solution and the gel was irradiated with UV light after electrophoresis. In Coomassie staining, gel is fixed in a 50% ethanol 10% glacial acetic acid solution for 1 hr. Then the solution is changed for fresh one and after 1 to 12 hrs gel is changed to a staining solution (50% methanol, 10% glacial acetic acid, 0.1% coomassie brilliant blue) followed by destaining changing several times a destaining solution of 40% methanol, 10% glacial acetic acid.
Despite the limited clinical experience in these decades, that era is remarkable for the demonstration of the role technology has in neuromodulation, and there are some case reports of deep brain stimulation for a variety of problems, real or perceived. Delgado hinted at the power of neuromodulation with his implants in the bovine septal region and the ability of electrical stimulation to blunt or alter behavior. Further attempts at this "behavioral modification" in humans were difficult and seldom reliable, and contributed to the overall lack of progress in central nervous system neuromodulation from that era. Attempts at intractable pain syndromes were met with more success, but again hampered by the quality of technology. In particular, the so-called DBS "zero" electrode (consisting of a contact loop on its end) had an unacceptable failure rate, and revisions were fraught with more risk than benefit. Overall, attempts at using electrical stimulation for "behavioral modification" were difficult and seldom reliable, slowing development of DBS. Attempts at addressing intractable pain syndromes with DBS were met with more success, but again hampered by the quality of technology. A number of physicians who hoped to address hitherto intractable problems sought development of more specialized equipment; for instance, in the 1960s, Wall's colleague Bill Sweet recruited engineer Roger Avery to make an implantable peripheral nerve stimulator. Avery started the Avery Company, which made a number of implantable stimulators.
===== Finasteride ===== Finasteride is used to treat male pattern hair loss. Treatment provides about 30% improvement in hair loss after six months of treatment, and effectiveness only persists as long as the drug is taken. There is no good evidence for its use in women. It may cause gynecomastia, erectile dysfunction and depression.
=== Scalp conditions === Dandruff – a common problem caused by excessive shedding of dead skin cells from the scalp Head lice infestation Excoriation disorder – obsessive skin picking Trichotillomania – obsessive hair pulling Seborrhoeic dermatitis – a skin disorder causing scaly, flaky, itchy, red skin Cradle cap – a form of seborrhoeic dermatitis which occurs in newborns Trichodynia – burning scalp syndrome Tinea capitis - ringworm of the scalp, and its severe form Favus Cutis verticis gyrata – a rare deformity of the scalp
Sources: en.wikipedia.org
NMN is commonly detected by HPLC-UV, LC-MS, or LC-MS/MS. These methods separate the compound from related substances and identify it by retention time and mass.
Laboratory samples are typically stored at -20°C or below, protected from light and moisture. Solutions are usually prepared fresh because they can degrade more quickly than the solid.
Purity depends on the analytical method, detection wavelength, and integration parameters. A value from one laboratory may not be directly comparable to another without method details.
NMN stands for nicotinamide mononucleotide. It is a nucleotide composed of nicotinamide, ribose, and phosphate. In cells, it is an intermediate in NAD+ biosynthesis.